Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency
Science · 2026
DOI: 10.1126/science.adz4075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2026. Verfasst von Zexiong Lin und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Ko…. Hauptthemen laut MEDLINE: Antifibrotic Agents, Fertility, Infertility, Female, Primary Ovarian Insufficiency. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Commission, Shenzhen High-level Hospital Construction Fund.
Abstract (Originalsprache)
Currently, no effective treatment exists for infertility associated with premature ovarian insufficiency (POI) because affected patients lack hormone-responsive antral follicles. By screening a Food and Drug Administration (FDA)–approved drug library, we identified finerenone, a kidney disease medication, as a promising drug for restoring fertility in POI. Finerenone stimulated follicle development in aged mice and restored antral follicle development in patients with POI following oral administration, resulting in mature oocytes and embryos. Mechanistically, finerenone reduced fibrotic deposition in the ovarian stroma, alleviating collagen-mediated suppression of follicular development. Building on this insight, we identified additional FDA-approved oral antifibrotic drugs as potential treatments for POI-related infertility. Our findings highlight the ovarian stroma—rather than the follicles themselves—as the key therapeutic target and offer potential therapeutic leads for POI-related infertility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
- Shenzhen Key Laboratory of Fertility Regulation, Center of Assisted Reproduction and Embryology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.
- Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Center of Reproductive Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Shenzhen Guangming District People's Hospital, Shenzhen, China.
- Department of Reproductive Center, Peking University-Shenzhen Hospital, Shenzhen, Guangdong, China.
ORCID-Profile: Zexiong Lin, Yuan Li, Yu Zhao, Dongteng Liu, Shuzi Deng, Jingkai Gu, Xudong Zhao, Yiting Sun, Yihui Zhang, Yin Lau Lee, Yorino Sato, Haonan Lu, Jennifer K Y Ko, Ernest H Y Ng, Yu Li, Karen K L Chan, William S B Yeung, Tianren R Wang, Kui Liu
Förderung
- Shenzhen Science and Technology Innovation Commission
- Shenzhen High-level Hospital Construction Fund
Zitieren
APA
Lin, Z., Li, Y., Zhao, Y., Liu, D., Deng, S., Gu, J., Li, Y., Zhao, X., Wu, P., Xiao, Y., Su, J., Sun, Y., Zhang, Y., Lee, Y. L., Sato, Y., Zeng, H., Lu, H., Zhang, J., Ko, J. K. Y., …, & Liu, K. (2026). Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency. Science. https://doi.org/10.1126/science.adz4075
Vancouver
Lin Z, Li Y, Zhao Y, Liu D, Deng S, Gu J, et al. Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency. Science. 2026. doi:10.1126/science.adz4075
BibTeX
@article{Lin2026,
author = {Lin, Zexiong and Li, Yuan and Zhao, Yu and Liu, Dongteng and Deng, Shuzi and Gu, Jingkai and Li, Yanyan and Zhao, Xudong and Wu, Peishan and Xiao, Yuan and Su, Jiaping and Sun, Yiting and Zhang, Yihui and Lee, Yin Lau and Sato, Yorino and Zeng, Haitao and Lu, Haonan and Zhang, Juanhui and Ko, Jennifer K Y and Zhao, Jing and Kawamura, Kazuhiro and Ng, Ernest H Y and Jiang, Shanfang and Li, Yu and Xia, Xi and Chan, Karen K L and Yeung, William S B and Wang, Tianren R and Liu, Kui},
title = {Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency},
journal = {Science},
year = {2026},
doi = {10.1126/science.adz4075}
}
EUVIMED